척수성 근위축증(SMA) 치료 시장 규모, 점유율 및 성장 분석 : 치료법별, SMA 유형별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Spinal Muscular Atrophy Treatment Market size was valued at USD 3.82 Billion in 2024 and is poised to grow from USD 4.23 Billion in 2025 to USD 9.52 Billion by 2033, growing at a CAGR of 10.62% during the forecast period (2026-2033).

The global spinal muscular atrophy treatment market is significantly influenced by the emergence of targeted disease-modifying therapies, which have shifted the focus from symptom management to genetic intervention for this debilitating neuromuscular disorder. Innovative therapies, such as those developed by leading manufacturers, have drastically improved life expectancy and reduced long-term care requirements, creating substantial commercial opportunities. The trend toward precision medicine, bolstered by advancements in genetic therapies and enhanced newborn screening programs, has allowed for early detection and treatment eligibility, improving patient outcomes. Additionally, AI technologies are accelerating drug development by enhancing target identification, optimizing clinical trial designs, and streamlining manufacturing processes. These developments foster collaboration with AI firms, facilitating faster progress toward effective therapies and enabling growth in emerging markets, thereby reshaping the treatment landscape for spinal muscular atrophy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Spinal Muscular Atrophy Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Spinal Muscular Atrophy Treatment Market Segments Analysis

Global spinal muscular atrophy treatment market is segmented by treatment type, sma type, administration, end-user and region. Based on treatment type, the market is segmented into Gene Therapy (Zolgensma), Antisense Oligonucleotides (Spinraza), Small Molecule (Evrysdi) and Supportive Care. Based on sma type, the market is segmented into SMA Type I, SMA Type II and SMA Type III. Based on administration, the market is segmented into Intrathecal, Oral and Intravenous. Based on end-user, the market is segmented into Hospitals, Specialty Neurology Centers and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Spinal Muscular Atrophy Treatment Market

The advancements in gene therapy for spinal muscular atrophy have significantly enhanced treatment options, offering more precise and long-lasting solutions that improve patient functionality while easing the ongoing burden of symptoms. Innovations in vector design, delivery strategies, and the deepening understanding of disease mechanisms have opened avenues for a wider range of therapeutic applications. This progress inspires ongoing investment and exploration within the clinical landscape, driving stakeholders such as healthcare professionals and manufacturers to prioritize research and expedite the development of new therapies. Consequently, this dynamic fosters the emergence of innovative treatment options and cultivates sustainable collaborations aimed at ensuring lasting benefits for patients.

Restraints in the Global Spinal Muscular Atrophy Treatment Market

The global spinal muscular atrophy treatment market faces significant barriers due to the high costs associated with therapies, which create affordability issues and restrict patient access. These elevated prices lead to increased scrutiny from payers and slow the adoption of beneficial clinical treatments. Additionally, the financial burden can deter healthcare systems from widely implementing new treatments, resulting in restrictive coverage policies and the need for prior authorization. This situation may discourage healthcare providers from prescribing such therapies and impact manufacturers' willingness to pursue broad commercialization. Ultimately, the market's growth is hindered by the necessity for price adjustments, evidence of value, and sustainable long-term affordability solutions to ensure access in various healthcare environments.

Market Trends of the Global Spinal Muscular Atrophy Treatment Market

The Global Spinal Muscular Atrophy Treatment market is witnessing a significant trend towards precision gene therapy, driven by an enhanced understanding of the disease mechanisms and innovations in vector technology. This advancement is paving the way for personalized, gene-based therapies that offer longer-lasting efficacy and potential cures. Industry stakeholders are increasingly focusing on tailored dosing strategies, engaging with regulatory bodies to innovate trial designs, and forming strategic partnerships to expedite the transition of research to clinical applications. Such dynamics not only cultivate competitive advantages for developers but also encourage investment in specialized manufacturing, reshaping both payer considerations and clinical pathways to ensure sustained positive patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Spinal Muscular Atrophy Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Gene Therapy (Zolgensma)
• Antisense Oligonucleotides (Spinraza)
• Small Molecule (Evrysdi)
• Supportive Care

Global Spinal Muscular Atrophy Treatment Market Size by SMA Type & CAGR (2026-2033)

• Market Overview
• SMA Type I
• SMA Type II
• SMA Type III

Global Spinal Muscular Atrophy Treatment Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Intrathecal
• Oral
• Intravenous

Global Spinal Muscular Atrophy Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Neurology Centers
• Home Care

Global Spinal Muscular Atrophy Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, SMA Type, Administration, End-User)
  • US
  • Canada
• Europe (Treatment Type, SMA Type, Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, SMA Type, Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, SMA Type, Administration, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, SMA Type, Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Biogen (Spinraza)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Zolgensma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Evrysdi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AveXis (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scholar Rock
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytokinetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wave Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Gene Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brainstorm Cell Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Passage Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Solid Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Design Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations